CompletedNot Applicable

TMS for Suicidal Crisis in Active Duty SMs

United States120 participantsStarted 2017-06-12

Plain-language summary

The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All Active Duty SMs (regardless of sex, ethnicity, sexual or religious orientation) who are admitted to Eisenhower Army Medical Center (EAMC) Inpatient Psychiatric Service (IPS) with active suicidality or elevated risk for suicide regardless of most psychiatric diagnostic co-morbidity (see exclusion criteria). This includes in-patient admissions for suicidality and outpatient SMs with a Columbia-Suicide Severity Rating Scale (C-SSRS) score ≥3. * Age 18 to 60 * Able to speak and read English. Exclusion Criteria: * Combative with staff. * Comatose/catatonia. * Incapacity owing to active mania or psychosis. * Epilepsy, multiple sclerosis, or cerebrovascular accident. * Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.) * Implantable devices (pacemakers, stimulators, etc.) * Schizophrenic or borderline personality. * Positive screen for pregnancy. * Already receiving TMS as a treatment for depression. * Non-English reading and speaking subjects

What they're measuring

Change in Suicidal Ideation (Acute)

Timeframe: Change over the active treatment course ie. the 3 days of active treatment

Trial details

NCT IDNCT03014362

SponsorEisenhower Army Medical Center

Sponsor typeFED

Study typeINTERVENTIONAL

Primary completion2020-01-10

Results submitted2022-03-28